During the last four decades, the optimal first-line treatment for chronic myeloid leukemia
(CML) in chronic (stable) phase has progressed from alkylating agents, to hydroxyurea (HU) …

Management decisions for patients with chronic myeloid leukemia (CML) have become
remarkably complex due to a variety of highly effective treatment options. Therapy for …

Imatinib (IM) at 400 mg daily has emerged as the preferred therapy for newly diagnosed
CML pts. Despite impressive results, only a minority of pts treated with IM achieved a …

Chronic myeloid leukemia (CML) is a stem cell disease characterized by the BCR/ABL
oncoprotein. The ABL kinase inhibitor imatinib is effective in most patients and considered …

The introduction of imatinib mesylate (Gleevec) to the therapeutic armamentarium has
changed the current management of chronic myelogenous leukemia (CML). With imatinib …

Elucidation of the pathogenesis of chronic myeloid leukemia (CML) and the introduction of
tyrosine kinase inhibitors (TKIs) has transformed this disease from being invariably fatal to …

Chronic myeloid leukemia (CML) treatment is based on company‐sponsored and academic
trials testing different tyrosine kinase inhibitors (TKIs) as first‐line therapy. These studies …

The introduction of imatinib, a specific inhibitor of the Bcr-Abl tyrosine kinase, has
dramatically changed the management of chronic myeloid leukemia (CML). More than …

Imatinib is remarkably effective in treating newly diagnosed patients with chronic myeloid
leukemia (CML) in chronic phase. However, at 5 years more than one third of the patients …

Imatinib is the therapeutic standard for newly diagnosed patients with chronic myeloid
leukemia (CML). Recent updates of the IRIS trial, a study of standard-dose imatinib in newly …